Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 29.19
2
Poor long term growth as Net Sales has grown by an annual rate of -1.36% over the last 5 years
3
Flat results in Jun 25
4
With ROE of 5.22%, it has a very attractive valuation with a 0.92 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
JPY 98,954 Million (Small Cap)
18.00
NA
0.02%
-0.26
6.53%
1.15
Revenue and Profits:
Net Sales:
9,500 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,224 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.51%
0%
3.51%
6 Months
36.54%
0%
36.54%
1 Year
53.27%
0%
53.27%
2 Years
80.7%
0%
80.7%
3 Years
63.36%
0%
63.36%
4 Years
37.55%
0%
37.55%
5 Years
113.32%
0%
113.32%
Katakura Industries Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.36%
EBIT Growth (5y)
12.92%
EBIT to Interest (avg)
29.19
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.24
Sales to Capital Employed (avg)
0.44
Tax Ratio
49.16%
Dividend Payout Ratio
46.43%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.23%
ROE (avg)
5.85%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
0.92
EV to EBIT
11.83
EV to EBITDA
7.47
EV to Capital Employed
0.89
EV to Sales
1.43
PEG Ratio
1.85
Dividend Yield
0.02%
ROCE (Latest)
7.51%
ROE (Latest)
5.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
9,500.00
11,255.00
-15.59%
Operating Profit (PBDIT) excl Other Income
2,122.00
2,400.00
-11.58%
Interest
34.00
32.00
6.25%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2,224.00
1,351.00
64.62%
Operating Profit Margin (Excl OI)
153.80%
150.70%
0.31%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -15.59% vs 3.91% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 64.62% vs 26.97% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
39,424.00
39,972.00
-1.37%
Operating Profit (PBDIT) excl Other Income
6,947.00
6,463.00
7.49%
Interest
141.00
108.00
30.56%
Exceptional Items
-902.00
-1,308.00
31.04%
Consolidate Net Profit
3,744.00
3,231.00
15.88%
Operating Profit Margin (Excl OI)
104.60%
95.20%
0.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -1.37% vs 16.62% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.88% vs 26.86% in Dec 2023
About Katakura Industries Co., Ltd. 
Katakura Industries Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






